South Korean Biotech Platforms Drive Surge in Multibillion-Dollar Global Licensing Deals
Monday, November 17, 2025
South Korea has rapidly emerged as a critical hub for pharmaceutical innovation, evidenced by a pronounced acceleration in its biotechnology firms securing multibillion-dollar licensing agreements with leading global pharmaceutical giants. Industry data released today highlight an unprecedented level of dealmaking activity in 2025, confirming Korea's rising influence in the pharmaceutical platform technology sector and setting the tone for a new era of cross-border R&D partnerships.
A major development was the recent technology-transfer agreement signed between ABL Bio and Eli Lilly, valued at up to US$2.56 billion. ABL Bio's proprietary "GrabBody" bispecific antibody platform, including its advanced GrabBody-B system, enables precision delivery of therapeutics designed to cross the blood-brain barrier via targeting the IGF1R receptor. This platform has attracted global attention as big pharma players strategically shift toward versatile, high-impact delivery systems that expedite molecule development and market accessibility. Earlier in the year, the same technology drew a separate 4-trillion-won agreement with GlaxoSmithKline, further cementing ABL Bio's reputation as a leader in next-generation antibody engineering.
The trend is not isolated. Alteogen, another Korean biotechnology company, has demonstrated consistent success in exporting its subcutaneous-injection platform, ALT-B4. This enzymatic technology transforms intravenous-administered drugs into subcutaneous formulations, offering significant improvements in ease of use and patient accessibility—drivers highly valued by global biopharma partners. Major licensing deals include a US$1.3 billion agreement with AstraZeneca’s MedImmune division and a US$300 million contract with Japan’s Daiichi Sankyo, solidifying the platform's appeal to multinationals seeking differentiated and scalable bioprocessing solutions.
Similarly, LegoChem Biosciences has deepened its global reach, transferring both its proprietary antibody-drug conjugate (ADC) technology and a pipeline candidate to Japan’s Ono Pharmaceutical, in a deal reportedly valued at 940 billion won. These agreements underscore a broader strategic movement: large pharmaceutical companies are increasingly prioritizing the acquisition of platform technologies—modular tools and frameworks that can be deployed across diverse R&D programs, thereby providing de-risked, high-return innovation potential compared to traditional single-asset drug deals. Such platforms enable earlier revenue recognition, reduce R&D burdens, and create deeper integration points for future commercial collaborations.
Korea’s platform technology market is also attracting new entrants. Samsung EpiS Holdings, a historically major player in biosimilars, has announced the launch of its new subsidiary, EpiS NexLab, to develop peptide and biologic-based platform technologies, signaling a strategic pivot toward next-gen molecules and value-added licensing opportunities. However, experts caution that while platform licensing generates substantial upfront and milestone revenues, Korean firms must continue to prioritize the development of full proprietary medicines if they are to achieve true "big pharma" global status and sustain long-term corporate valuations.
ABL Bio CEO Lee Sang-hoon recently emphasized, at the BIO International Convention in June, the need for Korean firms to pair platform successes with more aggressive investment in novel drug pipelines. While the current wave of lucrative licensing agreements validates Korea’s technical prowess, it also signals an evolving strategy among pharmaceutical executives, investors, and R&D leaders: blending platform licensing with in-house product innovation is emerging as the optimal model for both resilience and growth in an increasingly competitive global biopharma market.
As the Asian pharmaceutical landscape continues to mature, the significant rise in Korean platform technology deals sets a precedent for other Asia-based enterprises—demonstrating the value of innovation, partnership, and cross-border integration as key drivers of future industry leadership and global competitiveness.
